Clinical Trials Logo

Clinical Trial Summary

The purpose of the study is to evaluate the hypothesis that patients receiving remote ischemic conditioning using the autoRIC device show statistically significant reduction in the prevalence of ischemia-reperfusion injury to the myocardium as compared to patients in the autoRIC Sham device arm (within 12-24 hours post non-emergent PCI with stent implantation).


Clinical Trial Description

This is a multi-center, randomized, controlled single-blind clinical trial to evaluate the safety and effectiveness of the autoRIC device to attenuate myocardial injury as measured by cardiac Troponin I (cTnI) levels in patients undergoing PCI with stent implantation.

Eligible patients that are scheduled for an elective PCI, or unscheduled/non-emergent PCI, or patients scheduled for a diagnostic catheterization procedure with orders of "treat as indicated" will be enrolled in the study. Patients will undergo remote ischemic conditioning with the autoRIC device or the control procedure with the autoRIC Sham device completed ≤ 1 hour prior to balloon or stent inflation. Subjects will have measurements of cTnI levels at baseline and 4-8 and 12-24 hours post completion of the PCI procedure. Adverse events will be recorded through study exit for all patients. Patients will be exited from the study after completion of their 30-day post-procedure telephone follow-up. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03318575
Study type Interventional
Source CellAegis US, Inc.
Contact Vera Belaoussoff
Phone 647-722-9601
Email vbelaoussoff@cellaegisdevices.com
Status Recruiting
Phase N/A
Start date January 30, 2018
Completion date April 2019

See also
  Status Clinical Trial Phase
Recruiting NCT05327348 - Effectiveness of IV Vitamin C in Reducing Oxidative Stress Associated With Free Flap Surgery Phase 3
Completed NCT00184912 - The Effect of Caffeine on Ischemic Preconditioning N/A
Recruiting NCT05585255 - Clinical Significance of DKK2 Protein in Cerebral Ischemia-reperfusion Injury
Completed NCT05598177 - Effect of Dexmedetomidine Preconditioning on Myocardial Ischemia-reperfusion Injury in Patients Undergoing Open Heart Surgery With Cardiopulmonary Bypass Phase 4
Completed NCT04284592 - Remote Ischemic Postconditioning Increases HIF-1α Plasma Levels and Improves Cardiac Markers After Cardiac Surgery N/A
Withdrawn NCT00441714 - Effect of Ischemic Postconditioning on Targeting of Annexin A5 After Forearm Exercise N/A
Completed NCT00248040 - Reparixin in Prevention of Delayed Graft Function After Kidney Transplantation Phase 2
Completed NCT01486212 - Ischemia-reperfusion Injury Model on Healthy Volunteers and Measurement of Oxidative and Inflammatory Markers N/A
Recruiting NCT06097702 - A Study to Evaluate the Safety and Pharmacokinetics of BX-001N in Healthy Participants Phase 1
Completed NCT01073202 - Effects of Ursodeoxycholic Acid on Graft Recovery Early After Adult Liver Transplantation N/A
Completed NCT00224406 - Repertaxin in Prevention of Primary Graft Dysfunction After Lung Transplantation Phase 2
Completed NCT05246618 - FIH Phase I/IIa Trial Evaluating Safety of TUM012 to Minimize Ischemic Reperfusion Injury in Kidney Transplantation Phase 1/Phase 2
Completed NCT02118753 - The Effect of EPLerenone on Ischemia Reperfusion Injury in Human myoCARDium N/A
Completed NCT01739088 - Pediatric Remote Ischemic Pre-conditioning Prior to Complex Cardiac Surgery N/A
Completed NCT01040013 - Gut Oxygenation and Laparoscopy Phase 2
Suspended NCT00184847 - Adenosine Receptors Influence Ischemia-Reperfusion Injury N/A
Completed NCT01172171 - The Effect of Melatonin on Ischemia-reperfusion Injury Following Acute Myocardial Infarction Phase 2
Completed NCT00457405 - Does a Seven Day Treatment With Dipyridamole Induce Protection Against Ischemia-Reperfusion Injury? Phase 4
Completed NCT00184821 - Ischemic Injury and Ischemic Preconditioning in Diabetes N/A
Not yet recruiting NCT00691613 - Infusion of a Single Dose of Erythropoietin to Prevent Injury in an Ischemia Reperfusion Forearm Model N/A